Pirepemat Ph 2b rolling towards topline IRL757 Ph 1 studies ongoing Webcast today at 10:00 CET Even...
Redeye updates on W5 Solutions following Q3-results which were weaker than expected while order inta...
Redeye provides a preview on CoinShares, which is set to report on 5 November 2024.
Redeye raises its Base Case slightly following a Q3 report showing a relatively strong performance i...
Redeye provides a brief comment on Nitro Games’ expansion of Autogun Heroes to CrazyGames, one of th...
1% organic sales decline y-o-y Enmac had negative EBITA in Q3, actions taken Adj.
Q2 momentum gone in Q3 Market to turn positive in '25, according to report We lower '25e EBITA by 13...
Beijer Alma levererar ett stabilt kvartal med viss organisk tillväxt trots en inbromsning i konjunkt...
Redeye leaves a comment following Cinclus’ recent announcement that it has agreed on Paediatric Inve...
Finnair’s Q3 top line missed our estimate by almost 6% as average ticket fares continued to decrease...
LapWall's third quarter performance was solid, with net sales climbing in spite of a difficult marke...
Aspo’s Q3 earnings didn’t quite reach estimates as ESL’s EBITA remained low while Telko’s EUR 4.
Active Biotechs nya huvudfokus på myelofibros närmar sig start av två studier.
Redeye provides an update following Acconeer’s Q3 2024 results and updated go-to-market strategy.
Redeye comments on W5’s Q3-results which were weaker than expected while order intake continued to i...
